<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02407457</url>
  </required_header>
  <id_info>
    <org_study_id>CP-0011</org_study_id>
    <nct_id>NCT02407457</nct_id>
  </id_info>
  <brief_title>Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices</brief_title>
  <acronym>LEOPARD</acronym>
  <official_title>Multicenter, Post-Market Study to Assess Outcomes of Patients Treated With the AFX System Compared to Other EVAR Devices for Endovascular Abdominal Aortic Aneurysm Repair: LEOPARD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endologix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endologix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this post-market study is to evaluate Endologix AFX endovascular AAA system
      with anatomical fixation against other approved Endovascular systems with proximal fixation.
      Multiple U.S clinical centers will be involved in the study to include a broad range of
      experience. Imaging data will be evaluated by an independent core lab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, multi-center study, intended to evaluate the
      outcomes of contemporary EVAR (Endovascular Aneurysm Repair) in a real world population. The
      study is designed to compare the anatomically stabilized AFX Endograft System to a reference
      group of proximally fixated EVAR devices. Patients will be randomized between the two groups.

      Randomization will be 1:1. Each investigator will select one comparator device of their
      choice before enrolling the first patient. The study will sequentially evaluate
      non-inferiority and superiority hypotheses.

      Up to 80 sites with experience in EVAR and up to 800 subjects will participate in this study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of participants with Absence of Aneurysm Related Complications (ARC)</measure>
    <time_frame>1 year</time_frame>
    <description>ARC is a composite of the most relevant EVAR outcomes and includes:
Peri-Operative Death (&lt; 30 days)
Rupture
Conversion to OSR
Endoleaks; post-operative
Migration (≥ 10mm)
Aneurysm Enlargement (≥ 5mm)
Endograft Limb Occlusions
Reinterventions for device- or aneurysm-related complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of MAEs</measure>
    <time_frame>At 30 days, 12 months, and annually up to five years</time_frame>
    <description>Major Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of Aneurysm Related Complications (ARC)</measure>
    <time_frame>Post 12 Months up to Five Years</time_frame>
    <description>ARC is a composite outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants with Aneurysm Related Mortality</measure>
    <time_frame>Up to Five Years</time_frame>
    <description>Death related to the aneurysm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Endoleaks Classified by Type</measure>
    <time_frame>Up to Five Years</time_frame>
    <description>All Endoloeaks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of Neck Apposition as measured by length in mm</measure>
    <time_frame>Up to Five Years</time_frame>
    <description>Loss of Neck Apposition as measured by length in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AAA Related Secondary Procedures</measure>
    <time_frame>Up to Five Years</time_frame>
    <description>Number of AAA related secondary procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Device integrity events</measure>
    <time_frame>Up to Five Years</time_frame>
    <description>Number of device integrity events from device fractures and technical observations related to the stent graft</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adjunctive procedures necessitated during the implant procedure.</measure>
    <time_frame>Up to Five Years</time_frame>
    <description>Number of adjunctive procedures done during the implant procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Abdominal Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>AFX EVAR AAA Graft System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to receive the Endologix AFX Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDA Approved EVAR AAA Graft Systems</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AFX EVAR AAA Graft System</intervention_name>
    <description>Endvovascular Abdominal Aneurysm Repair (EVAR) using commerically available, FDA approved endovascular graft systems implanted via femoral access.</description>
    <arm_group_label>AFX EVAR AAA Graft System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FDA Approved EVAR AAA Graft Systems</intervention_name>
    <arm_group_label>FDA Approved EVAR AAA Graft Systems</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female at least 18 years old

          2. Subjects with minimum of 2 year life expectancy

          3. Subjects have signed the informed consent document for data release

          4. Subjects with AAA and eligible for endovascular Abdominal Aortic Aneurysm Repair

        Exclusion Criteria:

          1. Currently participating in another study where primary endpoint has not been reached
             yet

          2. Known allergy to any of the device components

          3. Pregnant (females of childbearing potential only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Kwolek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endologix</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North MS Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Prinssen M, Verhoeven EL, Buth J, Cuypers PW, van Sambeek MR, Balm R, Buskens E, Grobbee DE, Blankensteijn JD; Dutch Randomized Endovascular Aneurysm Management (DREAM)Trial Group. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med. 2004 Oct 14;351(16):1607-18.</citation>
    <PMID>15483279</PMID>
  </results_reference>
  <results_reference>
    <citation>Volodos' NL, Karpovich IP, Shekhanin VE, Troian VI, Iakovenko LF. [A case of distant transfemoral endoprosthesis of the thoracic artery using a self-fixing synthetic prosthesis in traumatic aneurysm]. Grudn Khir. 1988 Nov-Dec;(6):84-6. Russian.</citation>
    <PMID>3220297</PMID>
  </results_reference>
  <results_reference>
    <citation>Greenhalgh RM, Brown LC, Kwong GP, Powell JT, Thompson SG; EVAR trial participants. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial. Lancet. 2004 Sep 4-10;364(9437):843-8.</citation>
    <PMID>15351191</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown LC, Greenhalgh RM, Thompson SG, Powell JT; EVAR Trial Participants. Does EVAR alter the rate of cardiovascular events in patients with abdominal aortic aneurysm considered unfit for open repair? Results from the randomised EVAR trial 2. Eur J Vasc Endovasc Surg. 2010 Apr;39(4):396-402. doi: 10.1016/j.ejvs.2010.01.002. Epub 2010 Jan 21.</citation>
    <PMID>20096611</PMID>
  </results_reference>
  <results_reference>
    <citation>Stroupe KT, Lederle FA, Matsumura JS, Kyriakides TC, Jonk YC, Ge L, Freischlag JA; Open Versus Endovascular Repair (OVER) Veterans Affairs Cooperative Study Group. Cost-effectiveness of open versus endovascular repair of abdominal aortic aneurysm in the OVER trial. J Vasc Surg. 2012 Oct;56(4):901-9.e2. doi: 10.1016/j.jvs.2012.01.086. Epub 2012 May 27.</citation>
    <PMID>22640466</PMID>
  </results_reference>
  <results_reference>
    <citation>De Bruin JL, Baas AF, Buth J, Prinssen M, Verhoeven EL, Cuypers PW, van Sambeek MR, Balm R, Grobbee DE, Blankensteijn JD; DREAM Study Group. Long-term outcome of open or endovascular repair of abdominal aortic aneurysm. N Engl J Med. 2010 May 20;362(20):1881-9. doi: 10.1056/NEJMoa0909499.</citation>
    <PMID>20484396</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 6, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2015</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 7, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02407457/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>June 22, 2020</submitted>
    <returned>July 8, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

